NeoStem, Inc. (NYSE Amex: NBS) has been selected as the "Best Stem Cell Company, 2010" in The New Economy's Biotech Awards, which identify excellence in the field of technology.

The respected U.K. based and editorially independent magazine introduces its readers to exceptional thinking and progress in the fields of energy, finance, international affairs, science and technology.

According to The New Economy's editor Jan Spiegel, who chaired the panel overseeing the awards, "Biotechnology is an exciting field, perhaps nowhere more so than in the area of adult stem cells. The building of NeoStem's adult stem cell platform and its leadership role in this field has been gaining increased recognition including from the Pontifical Council for Culture of the Vatican in the recently announced exclusive collaboration."

Neostem's stock has recently overreacted to fear of dilution based on a $5 million financing despite the historic backing from The Vatican, very affirmative revenue projections and other positive developments involving its China based Suzhou Erye Pharmaceutical Company- which reported over $11 million dollars in revenues for 2009. Street analysts believe the revenues for those operations should be over $80 million and potentially higher in 2010 given the acceleration and relocation of the company's new production plant. Those efforts have doubled Suzhou Erye's capacity.

This month, Neostem also became the market's first commercial stem cell company with new revenue generating operations in the field of orthopedics as well as collection and storage in China. "NeoStem's VSEL(TM) technology represents the cornerstone of our R&D efforts to advance stem cell treatments in two of the world's largest pharmaceutical markets, US and China," said Robin Smith, NeoStem's Chairman and CEO.

Investors continue to receive signals like this that indicate just how undervalued shares of NBS are and there is speculation that the company is poised to make more moves which will ensure sustained growth and greater profit margins. In fact, in recent months, insiders in the company also increased their buying of shares, through the purchase of warrants, at a price much higher than where the stock is trading today. Commercial efforts by NeoStem in the field of anti-aging are set to begin shortly.

Dr. Smith will accept the award at a presentation and interview to be held at the London Stock Exchange this coming Thursday, July 8, 2010 at 11:00 a.m. GMT.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

---

Add this page to your favorite Social Bookmarking websites